EGFR and lung carcinoma: Although EGFR TKIs are potent in inhibiting the kinase activity of wild-type EGFR, cancers expressing wild-type EGFR, such as lung cancer (128–131), head and neck cancers (132), prostate cancer (133), and ovarian cancer (134), do not respond to TKIs regardless of the expression level of EGFR.